Long‐acting inhaled therapy (beta‐agonists, anticholinergics and steroids) for COPD: a network meta‐analysis

KM Kew, S Dias, CJ Cates - Cochrane Database of Systematic …, 2014 - cochranelibrary.com
Long‐acting inhaled therapy (beta‐agonists, anticholinergics and steroids) for COPD: a
network meta‐analysis - Kew, KM - 2014 | Cochrane Library Skip to Content Cookies Our site …

Long‐acting beta2‐agonists for chronic obstructive pulmonary disease

KM Kew, C Mavergames… - Cochrane Database of …, 2013 - cochranelibrary.com
Background Chronic obstructive pulmonary disease (COPD) is a respiratory disease that
causes progressive symptoms of breathlessness, cough and mucus build‐up. It is the fourth …

Espirometría

F García-Río, M Calle, F Burgos, P Casan… - Archivos de …, 2013 - Elsevier
Spirometry is the main pulmonary function test and is essential for the evaluation and
monitoring of respiratory diseases. Its utility transcends the field of Respiratory Medicine, is …

[HTML][HTML] Guidelines for diagnosis and management of chronic obstructive pulmonary disease: Joint ICS/NCCP (I) recommendations

D Gupta, R Agarwal, AN Aggarwal, VN Maturu… - Lung India, 2013 - journals.lww.com
Chronic obstructive pulmonary disease (COPD) is a major public health problem in India.
Although several International guidelines for diagnosis and management of COPD are …

No room to breathe: the importance of lung hyperinflation in COPD

M Thomas, M Decramer, DE O'Donnell - Primary Care Respiratory …, 2013 - nature.com
Patients with chronic obstructive pulmonary disease (COPD) are progressively limited in
their ability to undertake normal everyday activities by a combination of exertional dyspnoea …

[HTML][HTML] Longitudinal stability of asthma characteristics and biomarkers from the Airways Disease Endotyping for Personalized Therapeutics (ADEPT) study

PE Silkoff, M Laviolette, D Singh, JM FitzGerald… - Respiratory …, 2016 - Springer
Background Asthma is a biologically heterogeneous disease and development of novel
therapeutics requires understanding of pathophysiologic phenotypes. There is uncertainty …

Clinical significance of bronchodilator responsiveness evaluated by forced vital capacity in COPD: SPIROMICS cohort analysis

IZ Barjaktarevic, RG Buhr, X Wang, S Hu… - … journal of chronic …, 2019 - Taylor & Francis
Objective Bronchodilator responsiveness (BDR) is prevalent in COPD, but its clinical
implications remain unclear. We explored the significance of BDR, defined by post …

Effects of mometasone furoate/formoterol fumarate fixed-dose combination formulation on chronic obstructive pulmonary disease (COPD): results from a 52-week …

DE Doherty, DP Tashkin, E Kerwin… - … journal of chronic …, 2012 - Taylor & Francis
Rationale The purpose of this study was to investigate the clinical efficacy and safety of a
fixed-dose combination of mometasone furoate/formoterol fumarate (MF/F) administered via …

[HTML][HTML] Joint Indian chest society-national college of chest physicians (India) guidelines for spirometry

AN Aggarwal, R Agarwal, S Dhooria, KT Prasad… - Lung India, 2019 - journals.lww.com
Although a simple and useful pulmonary function test, spirometry remains underutilized in
India. The Indian Chest Society and National College of Chest Physicians (India) jointly …

Pharmacological assessment of the onset of action of aclidinium and glycopyrronium versus tiotropium in COPD patients and human isolated bronchi

P Rogliani, L Calzetta, J Ora, R Lipsi, A Segreti… - European Journal of …, 2015 - Elsevier
Preclinical studies suggested that aclidinium and glycopyrronium might have a faster onset
of action than tiotropium. In this study we assessed the onset of action of aclidinium and …